Agios Pharmaceuticals, Inc. (AGIO) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Cambridge, MA, アメリカ. 現CEOは Brian Goff.
AGIO を有する IPO日 2013-07-24, 486 名の正社員, に上場 NASDAQ Global Select, 時価総額 $1.95B.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
